Cargando…

Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome

BACKGROUND: Contralateral delayed endolymphatic hydrops (CDEH) is a clinical entity characterized by fluctuating low frequency hearing loss and/or vertigo, mimicking Ménière’s disease (MD), that manifests after the appearance of severe non-hydropic hearing loss (NHHL) at the other ear. OBJECTIVES: t...

Descripción completa

Detalles Bibliográficos
Autores principales: Albera, Andrea, Canale, Andrea, Boldreghini, Marco, Lucisano, Sergio, Riva, Giuseppe, Albera, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese PLA General Hospital 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438629/
https://www.ncbi.nlm.nih.gov/pubmed/34548865
http://dx.doi.org/10.1016/j.joto.2021.02.003
_version_ 1783752384419201024
author Albera, Andrea
Canale, Andrea
Boldreghini, Marco
Lucisano, Sergio
Riva, Giuseppe
Albera, Roberto
author_facet Albera, Andrea
Canale, Andrea
Boldreghini, Marco
Lucisano, Sergio
Riva, Giuseppe
Albera, Roberto
author_sort Albera, Andrea
collection PubMed
description BACKGROUND: Contralateral delayed endolymphatic hydrops (CDEH) is a clinical entity characterized by fluctuating low frequency hearing loss and/or vertigo, mimicking Ménière’s disease (MD), that manifests after the appearance of severe non-hydropic hearing loss (NHHL) at the other ear. OBJECTIVES: to describe the clinical features and the course of 57 patients affected by CDEH. METHOD: this is a retrospective study; 57 patients affected by CDEH, out of 1065 patients seen in the same period and affected by MD, were subjected to otoscopy, PTA threshold evaluation, impedance testing, ABR, research of positioning nystagmus, vestibular function evaluated by means of bithermal caloric test under video-oculographic, and MRI with gadolinium. RESULTS: the CDEH was definite in 24 cases (42%), probable in 2 (4%) and possible in 31 (54%). The mean PTA threshold at the hydropic ear was 41 dB. At the last follow-up, 40 patients (70%) did not report vertigo or fluctuating hearing loss. Among the 17 patients who still reported symptomatology, 11 (64%) were affected by fluctuating hearing loss alone, 4 (23%) reported a subjective worsening of hearing loss and 2 (12%) an acute vertigo crisis. CONCLUSIONS: contralateral delayed endolymphatic hydrops is a relatively rare form of Ménière disease that manifests more frequently as a definite form or with fluctuating low-frequency hearing loss. The prognosis at a long term follow-up is relatively good in terms of vertigo resolution. Contralateral delayed endolymphatic hydrops rarely determines a severe hearing loss in the better ear.
format Online
Article
Text
id pubmed-8438629
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Chinese PLA General Hospital
record_format MEDLINE/PubMed
spelling pubmed-84386292021-09-20 Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome Albera, Andrea Canale, Andrea Boldreghini, Marco Lucisano, Sergio Riva, Giuseppe Albera, Roberto J Otol Research Article BACKGROUND: Contralateral delayed endolymphatic hydrops (CDEH) is a clinical entity characterized by fluctuating low frequency hearing loss and/or vertigo, mimicking Ménière’s disease (MD), that manifests after the appearance of severe non-hydropic hearing loss (NHHL) at the other ear. OBJECTIVES: to describe the clinical features and the course of 57 patients affected by CDEH. METHOD: this is a retrospective study; 57 patients affected by CDEH, out of 1065 patients seen in the same period and affected by MD, were subjected to otoscopy, PTA threshold evaluation, impedance testing, ABR, research of positioning nystagmus, vestibular function evaluated by means of bithermal caloric test under video-oculographic, and MRI with gadolinium. RESULTS: the CDEH was definite in 24 cases (42%), probable in 2 (4%) and possible in 31 (54%). The mean PTA threshold at the hydropic ear was 41 dB. At the last follow-up, 40 patients (70%) did not report vertigo or fluctuating hearing loss. Among the 17 patients who still reported symptomatology, 11 (64%) were affected by fluctuating hearing loss alone, 4 (23%) reported a subjective worsening of hearing loss and 2 (12%) an acute vertigo crisis. CONCLUSIONS: contralateral delayed endolymphatic hydrops is a relatively rare form of Ménière disease that manifests more frequently as a definite form or with fluctuating low-frequency hearing loss. The prognosis at a long term follow-up is relatively good in terms of vertigo resolution. Contralateral delayed endolymphatic hydrops rarely determines a severe hearing loss in the better ear. Chinese PLA General Hospital 2021-10 2021-02-26 /pmc/articles/PMC8438629/ /pubmed/34548865 http://dx.doi.org/10.1016/j.joto.2021.02.003 Text en © 2021 PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier (Singapore) Pte Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Albera, Andrea
Canale, Andrea
Boldreghini, Marco
Lucisano, Sergio
Riva, Giuseppe
Albera, Roberto
Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
title Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
title_full Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
title_fullStr Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
title_full_unstemmed Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
title_short Contralateral delayed endolymphatic hydrops: Clinical features and long term outcome
title_sort contralateral delayed endolymphatic hydrops: clinical features and long term outcome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438629/
https://www.ncbi.nlm.nih.gov/pubmed/34548865
http://dx.doi.org/10.1016/j.joto.2021.02.003
work_keys_str_mv AT alberaandrea contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome
AT canaleandrea contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome
AT boldreghinimarco contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome
AT lucisanosergio contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome
AT rivagiuseppe contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome
AT alberaroberto contralateraldelayedendolymphatichydropsclinicalfeaturesandlongtermoutcome